Upcoming event

Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages

  • Jayant K. Rane 1,
  • Sarah Greener 1,
  • Fiona M. Frame 1,
  • Vincent M. Mann 2,
  • Matthew S. Simms 2,
  • Anne T. Collins 1,
  • Daniel M. Berney 4,
  • Norman J. Maitland 1
1 YCR Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, UK 2 Hull York Medical School, University of Hull, Hull, East Yorkshire, UK 3 Department of Urology, Castle Hill Hospital, Cottingham, East Yorkshire, UK 4 Centre for Molecular Oncology and Imaging, Barts and London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Take home message

In benign prostatic hyperplasia (BPH), a small population of basal cells expresses high levels of telomerase. Basal and luminal cells can proliferate independently, implying distinct basal and luminal lineages and suggesting that telomerase-blocking drugs could inhibit epithelial hyperproliferation in BPH.

Publication: European Urology, Volume 69, Issue 4, April 2016, Pages 551-554

PII: S0302-2838(15)00956-2

DOI: 10.1016/j.eururo.2015.09.039

Benign prostatic hyperplasia (BPH) treatments have changed little over many years and do not directly address the underlying cause. Because BPH is characterised by uncontrolled cell growth, the chromosomal telomeres should be eroded in the reported absence or low levels of telomerase activity, but this is not observed. We investigated the telomere biology of cell subpopulations from BPH patients undergoing transurethral resection of prostate (TURP). Measurement of TERC, TERT, and telomerase activity revealed that only the epithelial stem-like and progenitor fractions expressed high levels of telomerase activity (p < 0.01) and individual enzyme components (p < 0.01). Telomerase activity and TERT expression were not detected in stromal cells. Telomere length measurements reflected this activity, although the average telomere length of (telomerase-negative) luminal cells was equivalent to that of telomerase-expressing stem/progenitor cells. Immunohistochemical analysis of patient-derived BPH arrays identified distinct areas of luminal hyperproliferation, basal hyperproliferation, and basal–luminal hyperproliferation, suggesting that basal and luminal cells can proliferate independently of each other. We propose a separate lineage for the luminal and basal cell components in BPH.

Patient summary

We unexpectedly found an enzyme called telomerase in the cells that maintain benign prostatic hyperplasia (BPH), suggesting that telomerase inhibitors could be used to alleviate BPH symptoms.

Morbidity and loss of quality of life due to benign prostatic hyperplasia (BPH) are relatively high. There are >210 million cases of BPH worldwide [1], and the histologic prevalence of BPH is approximately 80% at the age of 80 yr. BPH is characterised by uncontrolled but noninvasive growth of a variety of cell types in the prostate, ranging in frequency from adenomyofibromatous, fibromuscular, fibroadenomatous, stromal, to rare muscular compositions. Medical treatments for BPH include targeting of the smooth muscle cells by α1-adrenergic receptor inhibitor and use of steroid 5α-reductase inhibitors to target the androgen-signalling axis. These treatments take several months to show urinary flow rate benefits but perhaps are ineffective in targeting androgen-independent basal cell proliferation. Surgical intervention by transurethral resection relieves urinary flow obstruction.

In normal somatic cells, repeated cell divisions result in an erosion of the repetitive terminal DNA sequences, the telomeres. The ultimate result of extreme telomere shortening is stress signal–mediated apoptosis or senescence. An understanding of telomerase biology is crucial to comprehend the proliferative dynamics of a tissue. Increased telomerase can be detected in approximately 70–90% of human cancers, including prostate cancer [2]. Although BPH tissue also exhibits a proliferative index two to three times higher than normal prostate [3], telomerase remains undetectable or is only sporadically expressed [2]. The inability to detect telomerase in non–stem-like cells, including the differentiated basal and luminal cells (>95% of the lesion), could have been interpreted as absent or sporadic telomerase expression or activity patterns in previous whole-biopsy analyses [2].

We assessed expression of the RNA (TERC) and protein (TERT) components of telomerase enzyme, telomerase activity, and telomere length in uncultured human BPH-derived stem-like cells (SCs: Lin/CD31/EpCAM+/CD133+/CD44+2β1hi), transit amplifying cells (TAs: Lin/CD31/EpCAM+/CD133/CD44+2β1hi), committed basal cells (CBs: Lin/CD31/EpCAM+/CD133/CD44+2β1lo), luminal cells (LCs: Lin/CD31/EpCAM+/CD44/CD24+), and stromal cells (Lin/CD31/EpCAM) (Supplementary Fig. 1, Supplement 1) [4] and [5] freshly purified from BPH tissues (Supplementary Table 1). The expression of NANOG was also higher in SCs (Supplementary Fig. 2). Previously, we reported that TERT expression was undetectable in normal prostate epithelial SCs and TAs [6]. In human BPH, however, the SCs and TAs exhibited significant overexpression of both TERC and TERT compared with the more differentiated CBs and LCs and stromal cells (Fig. 1a and 1b). Telomerase activity was also exclusively restricted to the SC/TA compartment, apart from one CB sample (Fig. 1c). All biopsies were specifically taken from the transitional zone with no detectable prostate cancer lesions on histology from patients with serum prostate-specific antigen levels <4 ng/ml to reduce the possibility of contamination with (telomerase-positive) cancer cells (Supplementary Table 1). TERT expression and telomerase activity were undetectable in stromal cells, indicating that telomerase is not essential for stromal hyperproliferation in BPH—another intriguing disparity in earlier data.



Fig. 1 Telomerase biology in epithelial subpopulations derived from human benign prostatic hyperplasia. (a) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis for TERC expression (n = 5). Data normalised to RPLP0 expression. (b) qRT-PCR analysis for TERT expression (n = 5). Data normalised to RPLP0 expression. (c) qRT-PCR analysis to measure telomerase activity using TRAPeze RT telomerase detection kit (Millipore, Bedford, MA, USA) (n = 5). Data normalised to telomerase activity in the P4E6 cell line. (d) Relative telomere length determination using modified qRT-PCR method (n = 5). The telomere length for each patient sample was normalised to the individual patients’ lymphocyte telomere lengths. Error bars represent mean ± SD.*p < 0.05.**p < 0.01.***p < 0.001.BPH = benign prostatic hyperplasia; CB = committed basal cells; HI = heat inactivated control; LC = luminal cells; mRNA = messenger RNA; ND = not detected; SC = stem-like cells; TA = transit-amplifying cells.

Epithelial cell telomere length measurements revealed that telomerase-expressing SCs and TAs had longer telomeres than those of their immediate differentiated progeny, the telomerase-negative CBs (p < 0.01) (Fig. 1d). The relative telomere length of LCs, however, was almost equivalent to that of SCs and TAs and was always longer than telomere lengths of patient-matched CBs (p < 0.01). Because LCs do not exhibit any detectable telomerase activity (Fig. 1c) and are believed to be derived from basal cells, the paradoxical observation of longer LC telomeres compared with CBs suggests that basal and luminal cells may be derived from distinct SC progenitors.

We stained BPH sections to determine basal cell content (using TP63) and luminal cell content (using NKX3.1) (Fig. 2a) and showed that basal and luminal hyperproliferation can occur together and even independently of each other because the basal:luminal ratio was highly variable, ranging from 0.22 to 2.08 (Fig. 2b, Supplementary Fig. 3), providing further evidence that basal and luminal cells may indeed be derived from different progenitors.



Fig. 2 Distinct basal and luminal hyperproliferation in benign prostatic hyperplasia tissue. (a) Immunofluorescence analysis of formalin-fixed paraffin-embedded sections showing predominantly TP63+ (magenta) basal hyperproliferation (first panel), predominantly NKX3.1+ (green) luminal hyperproliferation (second panel), and simultaneous basal and luminal hyperproliferation (third panel) in patient-derived benign prostatic hyperplasia (BPH) tissues. The arrows indicate areas of hyperproliferation. All nuclei are stained blue (DAPI). (b) A box and whisker plot showing variation of basal to luminal ratios in BPH. The number of basal cells (nuclear TP63 staining) and luminal cells (present in gland, TP63 negative) were counted. Images were captured on a Nikon Eclipse TE300 fluorescent microscope (Nikon, Tokyo, Japan) or Axio Scan.Z1 slide scanner (Carl Zeiss Microscopy GmbH, Jena, Germany). Cells were counted by eye. A total of 2800 cells were counted from 13 patients. (c) Model for prostate epithelial stem cell fate in BPH: The stem-like cell differentiates into basal and luminal progenitors. Alternatively, luminal progenitors can be derived from basal progenitor cells. The luminal progenitor then differentiates into single or very limited luminal cells. The basal progenitor cell gives rise to several basal cells, which retain some proliferative potential. Because these basal cells do not exhibit telomerase activity, they possess shorter telomeres.

In human prostate, we have previously shown that SCs differentiate into CB cells via TA cells [4], unlike mouse cells, in which the situation is less clear [7]. The lineage of LCs, however, has not been determined in humans, although in vitro we can readily derive luminal cells from basal cells under specific culture conditions [5]. We now propose that basal and luminal cell lineages may develop separately in BPH and speculate that the prostate epithelial SCs can asymmetrically differentiate [8] into distinct basal and luminal progenitor cells, as shown in Figure 2c. In many other stem cell systems, the spindle orientation of progenitor progenies can determine their ultimate identity. The two-progenitor model may assist in understanding BPH pathogenesis, in which each progenitor and its progeny can expand independently or simultaneously to give rise to well-documented [9] areas of basal hyperproliferation, luminal hyperproliferation, or proliferation of both compartments, as shown in Figure 2a. If a basal progenitor cell differentiates into CBs, which retain limited proliferative potential in the absence of detectable telomerase activity, this will result in telomere shortening in CBs, for example, in basal cell hyperplasia, as shown in Figure 2a. In contrast, a luminal progenitor cell population expressing telomerase could expand and give rise to terminally differentiated luminal cells, which do not replicate, maintaining a telomere length similar to that of the luminal progenitors. Our data is in agreement with both Bonkhoff et al [10] and McNeal et al [11] with respect to the existence of a proliferative basal compartment in which the potential luminal progenitors derived from basal SCs exhibit characteristics of both basal and luminal phenotypes, analogous to castration-resistant Nkx3.1-expressing cells in mice [12]. The second implication of our model is that local inhibition of telomerase in BPH could be an alternative therapeutic strategy, as it will inhibit the proliferation both luminal and basal epithelial progenitors but perhaps not that of stromal cells. Because it is suggested that these progenitors function as a reservoir of proliferating epithelial cells in BPH, utilisation of novel and specific telomerase inhibitors such as Imetelstat (Geron Corp, Menlo Park, CA, USA) could prove to be a good adjuvant therapy for the management of BPH.


Author contributions: Norman J. Maitland had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Maitland, Rane.

Acquisition of data: Rane, Frame, Greener.

Analysis and interpretation of data: Maitland, Rane, Frame.

Drafting of the manuscript: Rane.

Critical revision of the manuscript for important intellectual content: Maitland, Rane, Collins, Berney, Frame.

Statistical analysis: Rane, Frame.

Obtaining funding: Maitland.

Administrative, technical, or material support: Mann, Simms, Collins, Berney.

Supervision: Maitland.

Other (specify): None.

Financial disclosures: Norman J. Maitland certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: The work was funded by Prostate Cancer UK (G2012-37) and PRO-NEST Marie-Curie network (J.K.R.), and Yorkshire Cancer Research (grant Y257PA, F.M.F. and N.J.M.). The human prostate tissue bank was funded by the Orchid Trust (D.B.). The sponsors were involved in the design and conduct of the study and collection and analysis of the data.

Acknowledgements: We would like to thank all of the patients and the urology surgeons L. Coombes, G. Cooksey and J. Hetherington (Castle Hill Hospital, Cottingham, UK). Thank you also to Megan Nash for immunofluorescence staining and counting and to Jerry Shay (University of Texas Southwestern, Dallas, TX, USA) for providing invaluable guidance on the telomerase and telomere measurement experiments. Davide Pellacani provided many useful discussions concerning the work.

  • [1] T. Vos, A.D. Flaxman, M. Naghavi, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet. 2012;380:2163-2196 Crossref
  • [2] A.K. Meeker. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol. 2006;24:122-130 Crossref
  • [3] N. Kyprianou, H. Tu, S.C. Jacobs. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996;27:668-675 Crossref
  • [4] G.D. Richardson, C.N. Robson, S.H. Lang, D.E. Neal, N.J. Maitland, A.T. Collins. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004;117:3539-3545 Crossref
  • [5] D. Pellacani, D. Kestoras, A.P. Droop, et al. DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death Differ. 2014;21:761-773 Crossref
  • [6] J.K. Rane, M.S. Simms, N.J. Maitland, Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6: telomerase expression and stem cells: urologic epithelial perspective. Eur Urol. 2014;65:e85-e86 Crossref
  • [7] M. Ousset, A. Van Keymeulen, G. Bouvencourt, et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol. 2012;14:1131-1138 Crossref
  • [8] E.S. Polson, J.L. Lewis, H. Celik, et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun. 2013;4:1623 Crossref
  • [9] D.G. Bostwick. The pathology of benign prostatic hyperplasia. P. Kirby, J.D. McConnell, J.M. Fitzpatrick (Eds.) Textbook of Benign Prostatic Hyperplasia. (Isis Medical Media, London, UK, 2002)
  • [10] H. Bonkhoff, U. Stein, K. Remberger. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate. 1994;24:114-118 Crossref
  • [11] J.E. McNeal, O. Haillot, C. Yemoto. Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate. 1995;27:258-268 Crossref
  • [12] X. Wang, M. Kruithof-de Julio, K.D. Economides, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461:495-500 Crossref